JANX

14.33

0.62% -0.09

Vorhandelsmarkt: 14.50 0.17 +1.19%

Janux Therapeutics Inc (JANX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$14.42

Offen:

$14.54

24-Stunden-Volumen:

1.23M

Relative Volume:

1.13

Marktkapitalisierung:

$873.58M

Einnahmen:

$10.00M

Nettoeinkommen (Verlust:

$-113.63M

KGV:

-7.8161

EPS:

-1.8334

Netto-Cashflow:

$-83.28M

1W Leistung:

-1.17%

1M Leistung:

-3.44%

6M Leistung:

-47.97%

1J Leistung:

-51.90%

1-Tages-Spanne:

$14.03

$14.83

1-Wochen-Bereich:

$13.96

$14.83

52-Wochen-Spanne:

$12.12

$35.34

Janux Therapeutics Inc Stock (JANX) Company Profile

Firmenname

Janux Therapeutics Inc

Sektor

Healthcare (1106)

Branche

Biotechnology (615)

Telefon

(858) 751-4493

Adresse

10955 VISTA SORRENTO PARKWAY, SAN DIEGO

Mitarbeiter

109

Twitter

Nächster Verdiensttermin

2026-05-14

Neueste SEC-Einreichungen

JANX's Discussions on Twitter

Compare JANX vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
JANX Janux Therapeutics Inc	14.33	873.58M	10.00M	-113.63M	-83.28M	-1.8334
VRTX Vertex Pharmaceuticals Inc	424.36	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.06B	5.36B	287.73M	924.18M	2.5229

Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-04-20	Herabstufung	Barclays	Overweight → Underweight
2026-04-15	Herabstufung	UBS	Buy → Neutral
2025-11-18	Eingeleitet	Wolfe Research	Peer Perform
2025-09-17	Eingeleitet	Barclays	Overweight
2025-09-10	Eingeleitet	Stifel	Buy
2025-09-10	Eingeleitet	Truist	Buy
2025-09-04	Eingeleitet	Guggenheim	Buy
2025-08-19	Eingeleitet	Piper Sandler	Overweight
2025-07-11	Eingeleitet	Raymond James	Outperform
2024-12-03	Bestätigt	BTIG Research	Buy
2024-12-03	Bestätigt	H.C. Wainwright	Buy
2024-11-22	Eingeleitet	Leerink Partners	Outperform
2024-10-24	Eingeleitet	UBS	Buy
2024-09-06	Eingeleitet	Stifel	Buy
2024-05-30	Eingeleitet	Scotiabank	Sector Perform
2024-03-21	Eingeleitet	BTIG Research	Buy
2024-03-20	Eingeleitet	Cantor Fitzgerald	Overweight
2023-04-06	Eingeleitet	Wedbush	Outperform
2022-11-14	Eingeleitet	William Blair	Outperform

Alle ansehen

Janux Therapeutics Inc Aktie (JANX) Neueste Nachrichten

May 04, 2026

Janux Therapeutics: Strong Buy As Pipeline Advances, Stock Trades Below Cash Value - Seeking Alpha

May 04, 2026

May 03, 2026

EX-99.1 - SEC.gov

May 03, 2026

Janux Therapeutics halts early stage cancer program in 'prudent' move - MSN

May 03, 2026

JANX stock edges up after hours after discontinuing cancer program in favor of remaining pipeline - MSN

May 03, 2026

May 02, 2026

How Janux Therapeutics Inc. (JANX) Affects Rotational Strategy Timing - Stock Traders Daily

May 02, 2026

Apr 30, 2026

Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX), Stryker (SYK) and CareDx (CDNA) - The Globe and Mail

Apr 30, 2026

Multiple Insiders Sold Janux Therapeutics Shares Presenting Weak Signs For Investors - simplywall.st

Apr 30, 2026

Apr 29, 2026

Guggenheim Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $68 - Moomoo

Apr 29, 2026

A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $24 to $68 - Moomoo

Apr 29, 2026

Apr 28, 2026

Janux ends development of tumor activated T cell engager asset - MSN

Apr 28, 2026

Janux Therapeutics, Inc. Files 8-K Report with SEC: Company Information and Key Disclosures (April 28, 2026) - Minichart

Apr 28, 2026

Janux Therapeutics Adjusts Board Class Structure for Director - TipRanks

Apr 28, 2026

JonesTrading Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $28 - Moomoo

Apr 28, 2026

Janux Therapeutics (NASDAQ: JANX) moves Dobmeier to Class II seat - Stock Titan

Apr 28, 2026

Janux Therapeutics | ARS: Annual Report to Security Holders - Moomoo

Apr 28, 2026

[ARS] Janux Therapeutics, Inc. SEC Filing - Stock Titan

Apr 28, 2026

Janux Therapeutics (JANX) sets 2026 virtual meeting, board elections and pay vote - Stock Titan

Apr 28, 2026

JonesTrading Has Lowered Expectations for Janux Therapeutics (NASDAQ:JANX) Stock Price - MarketBeat

Apr 28, 2026

BofA cuts Janux Therapeutics stock price target on pipeline changes By Investing.com - Investing.com Canada

Apr 28, 2026

Janux Therapeutics Halts Early Stage Cancer Program In 'Prudent' Move - Benzinga

Apr 28, 2026

Stifel Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $38 - Moomoo

Apr 28, 2026

Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development - BioSpace

Apr 28, 2026

Janux Therapeutics (JANX) price target decreased by 11.93% to 54.57 - MSN

Apr 28, 2026

Apr 27, 2026

Barclays downgrades Janux Therapeutics (JANX) - MSN

Apr 27, 2026

JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline - Stocktwits

Apr 27, 2026

Janux to Halt Development of Cancer Drug Candidate JANX008 - marketscreener.com

Apr 27, 2026

Janux discontinues EGFR-targeted cancer therapy development By Investing.com - Investing.com Canada

Apr 27, 2026

Apr 26, 2026

Here are the most and least likely M&A targets in biotech, according to Truist - MSN

Apr 26, 2026

Apr 24, 2026

Janux Therapeutics Announces Collaboration and Exclusive Worldwid - The National Law Review

Apr 24, 2026

Apr 23, 2026